Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 4Non-metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Hormone-sensitive Prostate Cancer 2Male Urogenital Diseases 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Non-Metastatic 1Non-metastatic Prostate Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1High-Risk Localized Prostate Cancer 1Healthy Volunteers 1Genital Diseases, Male 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Abiraterone Acetate 2onapristone 1niraparib 1gedatolisib 1gallium 68 PSMA-11 1darolutamide 1apalutamide 1abiraterone 1Imatinib Mesylate 1EPI-506 1BAY 86-7548 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Genital Diseases, Male × darolutamide × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡